Morning administration in older populations produces minimal GH elevation due to compounding factors: lower pituitary GH stores, higher basal somatostatin tone, and reduced receptor density
Growth hormone secretagogues like MK-677 (a ghrelin receptor agonist) face the same limitation: they cant override elevated somatostatin or suppressed GHRH signaling
When a peptide meets its receptor, its like a text message to the cell: Repair here, Make more collagen, or Turn down inflammation. Many therapeutic peptides are synthetic or lab-refined versions of molecules your body already produces, so they tend to work by amplifying or fine-tuning the bodys own signals rather than overriding them
This type of cell death can lead to a variety of pathological changes, including neurodegenerative diseases such as Alzheimers disease (AD), Parkinsons diseases (PD), cerebrovascular diseases such as stroke, psychiatric disorders such as depression and schizophrenia, neurodevelopmental disorders such as autism spectrum disorders, nerve damage and neuralgia, and brain tumors (Wang et al., 2024d
